AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02719730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reimbursement for whole grain purchases
Description: All participants will receive education about whole grain foods. Those in the experimental arm will have a monthly financial incentive for purchases of specific whole grain foods foods during the 12-week study period, whereas the control group will not have a financial incentive for whole grain purchases during the study period.
Study NCT01828515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Participants will be randomized to either vilazodone or placebo titrated as follows: 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days.
Study NCT01828515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02628847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Study NCT02628847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00907478 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: romiplostim
Description: Romiplostim administered by subcutaneous injection
Study NCT01945931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safe Delivery Smartphone Application
Description: The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The application is furthermore intended as a reference tool that could be used during clinical work for example for preparation before attending a birth, in a situation when a complication occurs, or for debriefing and self-evaluation after a complication. The application features four animated videos with clinical instructions of 3-8 minutes duration and written lists of essential obstetric drugs (indications, contraindications, dosage and administration and side effects) and essential equipment for a safe delivery.
Study NCT02474017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGR001
Description: Fluticasone Propionate / Salmeterol administered using CRC749 inhaler
Study NCT02474017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRC749 inhaler
Study NCT03053089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGT-181
Description: Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
Study NCT01748396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Study NCT01748396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Study NCT01748396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Study NCT01828515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Participants receive 160 mg x 4 days after vilazodone or placebo pre-treatment
Study NCT01704989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SLT Laser
Description: At the first treatment, SLT treatment will be delivered to 360 degrees of trabecular meshwork. At the first escalation of treatment, the superior 180 degrees will be retreated. Twenty-five non-overlapping shots per quadrant will be used with a starting power of 0.8 mJ and increments of 0.1 mJ (titrated to avoid large bubbles) with standard other settings (400 nm spot size, 3 nanosecond duration) using a Latina single-mirror goniolens. The IOP will be checked 1 hour post treatment and five days of guttae acular tds will be administered to the treatment eye following treatment. After 2 treatments of SLT, the laser treated arm of the study will follow the same pathway as the medical treatment arm.
Study NCT01704989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostagladin
Description: Treatment will be initiated with latanoprost 0.005%. At the first IOP check (1-2 months), if the IOP has not reached target IOP, a second line agent will be added (β-Blocker unless contraindicated). If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor). Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP. Surgical therapy will be considered if target IOP is not met, or there is high IOP (>35 mmHg) or advanced damage at presentation.
Study NCT01655069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension
Description: Oral suspension
Study NCT04491955 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301
Description: CV301 vaccine consists of MVA-BN-CV301 and FPV-CV301. MVA-BN-CV301 (4 x 10\^8 infectious units/0.5 mL each) will be administered as four subcutaneous injections on D1 and D15. Starting on D29, FPV-CV301 (1 x 10\^9 infectious units/ 0.5mL) will be administered as a single subcutaneous injection every 4 weeks on Arm 1 or every 6 weeks on Arm 2A and 2B for up to one year.
Study NCT04491955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0011359C
Description: Subjects will receive M7824 via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg or 300 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter.
Study NCT02086799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV thyroxin
Description: Patients will receive treatment with intra-venous thyroxine 100mcg once on admission and additional 100mcg after 12 hours.
Study NCT02086799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive treatment with normal saline 100ml once on admission and additional 100ml after 12 hours
Study NCT04491955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every four weeks on Arm 1. N-803 will be administered at as dose of 10 (Micro)g/kg by SC injection every 4 weeks on Arm 2A and Arm 2B.
Study NCT04491955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NHS-IL12
Description: NHS-IL12 will be given via subcutaneous injection at a dose of 8 mcg/kg every 4 weeks or 16 mcg/kg for the first 4 injections and 8 mcg/kg thereafter on Arms 2A and 2B.
Study NCT03646617 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy (HFRT)
Description: The dose of HFRT will be 8 Gy x 3 fractions, given over a maximum of 7 days timespan.
Study NCT03646617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses. After these 4 doses, the patient and investigator will decide to continue with nivolumab (240 mg) every 2 weeks or Nivolumab (480mg) every 4 weeks as monotherapy for up to one year as an IV infusion over 30 minutes.
Study NCT03646617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses. After these 4 doses, the patient and investigator will decide to continue with nivolumab (240 mg) every 2 weeks or Nivolumab (480mg) every 4 weeks as monotherapy for up to one year as an IV infusion over 30 minutes.
Study NCT03646617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses.
Study NCT03646617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses.
Study NCT04128748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study NCT04128748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given PO
Study NCT04424251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: stage I：HSK21542 0.4 μg/kg
Description: Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
Study NCT04424251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: stage I：HSK21542 1 μg/kg
Description: Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
Study NCT04424251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: stage I：HSK21542 0.5μg/kg
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
Study NCT04424251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: stage I：HSK21542 1μg/kg
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
Study NCT04424251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: stage II：HSK21542 0.5μg/kg
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
Study NCT04424251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: stage II：HSK21542 1μg/kg
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
Study NCT04424251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
Study NCT04308590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: relacorilant
Description: Relacorilant is supplied as 100 mg capsules for oral dosing.
Study NCT04308590 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as 100 mg capsules for oral dosing.
Study NCT04236804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flowly (TMC-CP01)
Description: TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.
Study NCT03268499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lipiodol-based transarterial chemoembolization
Description: Arterial catheterization to segmental, subsegmental, or sub-subsegmental level was achieved depending on the tumor size, to gain arterial access as close to the tumors as possible. The formulation was delivered under fluoroscopic control until the vasculature of all tumors was entirely filled, or until the maximum dose was reached.
Study NCT03268499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipiodol-based transarterial chemoembolization
Description: Arterial catheterization to segmental, subsegmental, or sub-subsegmental level was achieved depending on the tumor size, to gain arterial access as close to the tumors as possible. The formulation was delivered under fluoroscopic control until the vasculature of all tumors was entirely filled, or until the maximum dose was reached.
Study NCT01122368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micafungin
Description: IV
Study NCT01122368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV
Study NCT04729140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin Tablets
Description: Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
Study NCT04729140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Tablets
Description: Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
Study NCT04729140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
Study NCT01676480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: 12 weeks of endurance training 3 times per week
Study NCT00677027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lentinan
Description: Five dose levels of escalating concentrations of the test substance will be tested during the study periode. All patients will recieve each dose, which is to be taken daily for two weeks.
Study NCT00677027 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT01496573 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01943123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic drink
Description: comparison of study group (probiotic group) with the control group regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
Study NCT01943123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: plain, unsweetend, unflavored pasturised milk
Description: comparison of control group with the study group (probiotic group) regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
Study NCT01234402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab DP
Description: 10 mg/kg I.V.~Day 1 of every-21-day cycle
Study NCT01234402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-18F1
Description: 12 mg/kg I.V.~Days 1 and 8 of every-21-day cycle
Study NCT01234402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m\^2 orally~Twice a day for 14 days
Study NCT01234402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 orally~Twice a day for 14 days
Study NCT02643498 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Study NCT02301988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
Study NCT02301988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) as IV infusion QW for 3 cycles.
Study NCT02301988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) as IV infusion QW for 3 cycles.
Study NCT02301988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
Study NCT03859206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical thoracoscopy
Description: • With the closed biopsy forceps, step by step, fibrinous septae were perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken \& If no lesion, biopsy from parietal pleura was obtained from any sites.
Study NCT00883844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue treatment with a peginterferon add-on strategy
Description: peginterferon 1.5 microgram/kg once a week Treatment with one of the approved nucleos(t)ide analogues
Study NCT00883844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleos(t)ide analogue treatment
Description: Treatment with one of the approved nucleos(t)ide analogues
Study NCT02594332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: 100 mg SC every 4 weeks for 13 injections
Study NCT02594332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03866525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OH2 injection, with or without irinotecan or HX008
Description: OH2: Oncolytic Type 2 Herpes Simplex Virus Irinotecan: cytotoxic agent HX008: anti-PD-1 antibody
Study NCT02065115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice pack)
Study NCT03490279 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin CRX
Description: Patients will be asked to take lactoferrin CRX as already mentioned (blindly).
Study NCT03490279 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be asked to take placebo as already mentioned (blindly).
Study NCT04581135 — intervention group
Intervention type: OTHER
Intervention: COVID-19
Description: Research project in which biological material is sampled and health-related personal data are collected and used for further research. Coded data are used.
Study NCT04129502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsule
Study NCT04129502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed IV infusion
Study NCT04129502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin IV infusion
Study NCT04129502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV infusion
Study NCT03784365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: One dose of Cefo-perazone Sulbactum
Description: Antibiotic
Study NCT03784365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One dose of Cefo-perazone Sulbactum
Description: Antibiotic
Study NCT02937974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuebijing
Description: Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
Study NCT02937974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
Study NCT01669707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar -Continued Pumping into+GP
Description: Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 120 hours and the dosage is 7.5mg/m2\*5 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-4cycles.
Study NCT01669707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endostar -injecting into +GP
Description: Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-4cycles
Study NCT00990275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ethanol
Description: subjects will ingest 3 ounces of vodka mixed with fruit juice within 30 min.
Study NCT03785288 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HDR vaginal brachytherapy
Description: HDR vaginal brachytherapy 7 Gy in 3 fractions or HDR vaginal brachytherapy 4 Gy in 6 fractions
Study NCT04729140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
Study NCT03513861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FASTER Assessment tool
Description: The FASTER assessment tool consists of monitoring mental status, respiratory distress and capillary refill time by parents of children admitted to the hospital with febrile illness. Parents in the intervention group are asked to monitor their child hourly with the FASTER tool and signal severity of illness to the healthcare team via color coded flag system. Number of healthcare provider - patient reassessments will be compared in intervention and control group.
Study NCT03513861 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FASTER Assessment tool
Description: The FASTER assessment tool consists of monitoring mental status, respiratory distress and capillary refill time by parents of children admitted to the hospital with febrile illness. Parents in the intervention group are asked to monitor their child hourly with the FASTER tool and signal severity of illness to the healthcare team via color coded flag system. Number of healthcare provider - patient reassessments will be compared in intervention and control group.
Study NCT03945253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: Intravenous
Study NCT02567474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 A model
Description: self management program based on 5A model
Study NCT03984461 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous cell therapy
Description: Biologic material is harvested from the participant and re-injected into an osteoarthritic joint